首页> 外文期刊>Journal of artificial organs: The official journal of the Japanese Society for Artificial Organs >Efficacy of new pediatric extra-corporeal life support system (Endumo 2000) for postoperative management after Norwood operation
【24h】

Efficacy of new pediatric extra-corporeal life support system (Endumo 2000) for postoperative management after Norwood operation

机译:新的儿科体外生命支持系统(Endumo 2000)对诺伍德手术后的术后管理的功效

获取原文
获取原文并翻译 | 示例
       

摘要

This study aimed to assess the efficacy of a new pediatric extra-corporeal life support (ECLS) system (Endumo 2000, Heiwa Bussan, Tokyo, Japan) for postoperative management after the Norwood operation. Thirty-three consecutive patients with hypoplastic left heart syndrome or its variant undergoing the Norwood operation between August 2007 and December 2013 were divided into two groups according to available ECLS devices. Before November 2009, pediatric Emersave (TERUMO, Saitama, Japan) was employed as the ECLS device, and 14 patients were operated on during this period (Emersave era: 7 boys; 2.9 kg). After December 2009, Endumo 2000 was employed and 19 patients were operated on (Endumo era: 8 boys, 3.1 kg). The demographic characteristics of both groups showed no significant differences. ECLS was initiated in 7 of 14 patients (50 %) during the Emersave era and 7 of 19 patients (37 %) during the Endumo era (p = 0.45). Chest reentry for hemostasis during ECLS support was more frequently needed in patients supported by Emersave (5/7) than Endumo (1/7) (p = 0.03). The first ECLS circuit durability of Endumo was significantly longer than that of Emersave (p = 0.01). The survival at discharge rate in patients required ECLS was 0 % (0/7) when supported by Emersave, but 57 % (4/7) by Endumo (p = 0.02). As a result, the survival at discharge rate was 43 % (6/14) in the Emersave era and 79 % (14/19) in the Endumo era (p = 0.03). Longer durability and superior antithrombogenicity of the Endumo 2000 contributed to the improvement of surgical outcomes after the Norwood operation.
机译:这项研究旨在评估新的儿科体外生命支持(ECLS)系统(Endumo 2000,Heiwa Bussan,日本东京)在诺伍德手术后进行术后管理的功效。根据ECLS装置,将2007年8月至2013年12月间连续进行了Norwood手术的33例左心发育不全综合征或其变体患者分为两组。在2009年11月之前,儿科Emersave(日本Sa玉县TERUMO)被用作ECLS装置,在此期间有14例患者接受了手术(Emersave时代:7名男孩; 2.9公斤)。 2009年12月之后,雇用Endumo 2000,并进行了19例手术(Endumo时代:8名男孩,3.1公斤)。两组的人口统计学特征均无显着差异。在Emersave时代14位患者中有7位(50%)发起了ECLS,在Endumo时代19位患者中有7位(37%)发起了ECLS(p = 0.45)。 Emersave(5/7)支持的患者比Endumo(1/7)更加需要在ECLS支持期间进行胸腔再入止血(p = 0.03)。 Endumo的首次ECLS电路耐久性显着长于Emersave(p = 0.01)。在Emersave支持下,需要ECLS的患者出院率生存率为0%(0/7),而Endumo则为57%(4/7)(p = 0.02)。结果,Emersave时代的出院存活率为43%(6/14),Endumo时代的出院存活率为79%(14/19)(p = 0.03)。 Endumo 2000的更长的耐用性和优异的抗血栓形成性有助于诺伍德手术后手术效果的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号